Gt Biopharma, Inc. · NASDAQ:GTBP
Gt Biopharma — OXIS International — Investor Presentation (October 2015)
27 slides from Gt Biopharma's investor presentation, Oct 26, 2015
Slide 1: OXIS Biotech Corporate Overview Fall 2015
OXIS BIOTECH CORPORATE OVERVIEW FALL 2015
Slide 2: Forward Looking Statements
ee FORWARD LOOKING STATEMENTS cor H be identified by such terminology such as voxnects “potential ssugest “may”, or similar Sucl involve known and unknown risks, uncertaiides and other factors that mow cause the actual results to be materially different from any future results, performance or achiev
Slide 3: Immuno-Oncology Focus
IMMUNO-ONCOLOGY FOCUS Antibody-Drug Conjugates (ADC) Antibody Directed Cell-Mediated Cytotoxic Therapeutics (ADCC) aa
Slide 4: Highlights
HIGHLIGHTS v Vv Extensive clinical and preclinical pipeline: + Antibody-drug conjugates including novel dual-payload and bispecific ADCs + NK cell and T-cell bispecific and trispecific antibody directed cell- mediated cytotoxic therapeutics (ADCCs) One product candidate awaiting FDA allowance to pro
Slide 5: Antibody Drug Conjugate (ADC)
Slide 6: Antibody-Drug Conjugate Mechanism of Action
ANTIBODY-DRUG CONJUGATE MECHANISM OF ACTION @ ADC in plasma 2, SY v @ Adc binds to receptor e ADC-receptor complex is internalized © Apoptosis (cell death) Reference: Carter Plat al. Cancor/ 2008;14(3}154-169.
Slide 7: Antibody Directed Cell-Mediated Cytotoxicity (ADCC)
ANTIBODY DIRECTED CELL-MEDIATED Cytotoxicity (ADCC) 5 Immune Cell Triggers Destruction of Cancer Cell
Slide 8: Cytotoxic Mechanism of Action
CYTOTOXIC MECHANISM OF ACTION bee, rons on een aay YA 6 Granyme
Slide 9: Cytotoxic Mechanism of Action
CYTOTOXIC MECHANISM OF ACTION
Slide 10: Therapeutic Category Comparable
THERAPEUTIC CATEGORY COMPARABLE ~ BLINCYTO" BUNCYTO® (bak busonish) from be a firstin-lass (blinatumomab) Rion ly (ance). acute lymphoblastic leukemia. Wancetris ADCETRIS®(brentuximab vedotn) from Seattle vedotina cells. Adcetris
Slide 11: Comprehensive Immuno-Oncology Technology Platform
COMPREHENSIVE IMMUNO-ONCOLOGY TECHNOLOGY PLATFORM Antibody-Drug Conjugate (ADC) Therapeutic Platform > scFvs targeting CD19, CD22, CD33, CD133, EpCAM, G72 > Full-length human MAbs targeting ICAM, FZD7, 038 » Payloads: OXS-4235, OXS-2175, Diphtheria Toxin, Pseudomonas Exotoxin Antibody Directed Cell-
Slide 12: Proprietary ADC Drug Payloads
PROPRIETARY ADC DRUG PAYLOADS Oxs-4235 . Inhibitor of p62/Sequestosome 1 resulting in autophagy- rected multiple myeloma cell death and TNFa: inhibition improving osteogenesis y > OXS-2175 ‘Targets Inhibitor of ONA Binding 1 (Id-1) Protein which their activation Deimmunized Recombinant Diphtheria To
Slide 13: Robust Product Pipeline
ROBUST PRODUCT PIPELINE Product Therapeutic IND Enabling Studies ‘Candidate Desciotion / Indication _Gategory AD GMPManufacturingBhase Phase? (OxS-1550Ant-cb19/Ant-cD22/0T Bispecitic Pen ots > (OXS-1650_Ant-EpCAM/Ant-CD133/PEKDEL (netactory Epithelial Ovarian cancer) i —— ‘apc 0xs-3550 pee (Gat main
Slide 14: OXS-1550 Initial Phase Study Results
OXS-1550 INITIAL PHASE 1 STUDY RESULTS A. Bobo therapy era single course of DT2219 S § / > Panel A: Partial Response in 77 yr old oh patient with refractory chronic lymphocytic leukemia B Boteothorapy > Panel B: Complete Response in 53 yr old patient with refractory marginal zone lymphoma which is o
Slide 15: Initial Clinical Experience Summary
INITIAL CLINICAL EXPERIENCE SUMMARY Infusior XS-1550 to emt and gives it time to work despite 2 relatively shor, 1-11 hour hal-ife which is not atypical or bispectc scFv therapeutics, e.g., see prescribing information SINGYTO® (1.42 hour a bispecific scFv) versus Adcetris® (4-6 days — a full-length
Slide 16: OXS-1550 Pending Phase I/II Clinical Trial
— -QX§-1550—i( wt:t~‘i‘t:*W PENDING PHASE I/II CLINICAL TRIAL Study Te: and/or €O 22 (+) Bineage Leukemia or Lymphoma Pr v2, MD, PHO IND Sponsor: Danie! Valera, PRD > Gineat Tal ste: Masonie Cancer Center, University of Minnesota andjor unacceptable tonicity. Dose cohorts: 0,60, 80 ng/ke/dose. > Enl
Slide 17: Product Candidate Summary
—_ PRODUCT CANDIDATE SUMMARY
Slide 18: ussipon Indo
ussipon Indo ‘anton cocoa ree ‘incr trent bape mee ‘Seethemensane soe
Slide 19: Intellectual Property
INTELLECTUAL PROPERTY Powerful intellectual property position » Comprehensive patent portfolio, worldwide exclusive rights fully supporting the development and commercialization of innovative immuno-oncology therapeutics. Portfolio covers compositions of matter and methods of use in each > 1 pending
Slide 20: Market Opportunity
MArKET OPPORTUNITY = Multiple Myeloma > tects = Triple-Negative Breast Cancer : mately 15%-20% of all breast cancer cases. > Affects 23: ing about 40,350 deaths last your = Refractory Evithellal Svarion Cancer Epithelial carcinoma of ry is one of the most common gynecologic malignancies the Han moo!
Slide 21: People
PEOPLE = Managemer > Anthony J. Cataldo, Chairman & Chief Executive Officer > Steven Weldon, MBA, CPA, Chief Financial Officer *Sclentific Advisory Board > James MOFFITT @) IMottt Cancer Coster Research sate, 128 > Cassin Yeo, M.D, Professor, Department of Immunology, Divi MiAnderson ancee ener ion
Slide 22: Board of Advisors
BOARD OF ADVISORS the Oxis Board of Directors Our Board will bec upon a successful up-listing to the NASDAQ exchange “a | ewe Enterta id Take > Randolph Read N NEW YORK REIT + Currently serves on the Boards of New York REIT (Chairman), Healthcare Trust Board of the Fiying Food Group > Michael sitric
Slide 23: Financials & Capitalization
FINANCIALS & CAPITALIZATION Proforma Post 250:1 Reverse Split** $4.175 2,400,000 12,609,827 11,906 15,021,733 $0.00 $125,000 $50.00 +, Slosing price was 820167 on October 2, 2018; Assuming 2280: stock sl “Approval of reverse stock split ‘ot nos tet Soo] ly te Gi S80 fora ne gril oy ban of SONS. shar
Slide 24: Value Creation Strategy
VALUE CREATION STRATEGY * One Product Candidate Awaiting FDA Allowance to Proceed with Phase I/II Clinical Trial > OXS-1550 (Anti-CD19/Anti-CD22/DT Bispecific ADC; Acute lymphoblastic leukemia & Non-Hodgkin’s lymphoma) = Four Product Candidates Entering Clinic within 18-24 Months > OXS-1650 (Anti-Ep
Slide 25: Value Creation Strategy
VALUE CREATION STRATEGY * Pharma / Biotech Company Partnering Opportunities » Rich Immuno-Oncology Product Pipeline ADCC & ADC logy » Strong ADC and ADC Intellectual Property > NK Cell ADCC Engagers » T-Cell ADCC Engagers > Combit i Land Id-1
Slide 26: Summary
SUMMARY v Vv Extensive clinical and preclinical pipeline: + Antibody-drug conjugates including novel dual-payload and bispecific ADCs + NK cell and T-cell bispecific and trispecific antibody directed cell- mediated cytotoxic therapeutics (ADCCs) One product candidate awaiting FDA allowance to procee
Slide 27: OXIS Biotech Corporate Overview Fall 2015
OXIS BIOTECH CORPORATE OVERVIEW FALL 2015
OXIS International — Investor Presentation (October 2015) on 6ix